Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.61 |
| ▸ | JAK3 | P52333 | 10/20 | 0.61 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.61 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.57 |
| ▸ | CDK2 | P24941 | 4/20 | 0.57 |
| ▸ | RET | P07949 | 2/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.57 |
| ▸ | MUSK | O15146 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.57 |
| ▸ | PLK4 | O00444 | 4/20 | 0.47 |
| ▸ | PAK4 | O96013 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KHK | P50053 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621822 | 0.87 | PLK4 (0.49) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2490902 | 0.87 | JAK2 (0.64) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2565184 | 0.87 | JAK3 (0.57) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2490881 | 0.81 | JAK2 (0.48) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL2489276 | 0.81 | JAK2 (0.63) | JAK2JAK3NTRK1CDK2 | |
| SCHEMBL1623799 | 0.77 | JAK3 (0.45) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL12720706 | 0.77 | MEN1 (0.45) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL14840366 | 0.76 | JAK2 (1.00) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL18165211 | 0.76 | JAK2 (0.85) | JAK2JAK3LIMK1LIMK2NTRK1 | |
| SCHEMBL29349780 | 0.76 | JAK2 (1.00) | JAK2JAK3LIMK1LIMK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1876178-B1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-05-27 | — | — | EP | claimed |
| US-20090292121-A1 | Cyanopyridine derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | claimed |
| EP-1876178-A1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-01-09 | — | — | EP | claimed |
| US-20220233513-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2022-07-28 | — | — | US | disclosed |
| EP-1876178-B1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-7928126-B2 | Cyanopyridine derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7928126-B2 | Cyanopyridine derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20090292121-A1 | Cyanopyridine derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090292121-A1 | Cyanopyridine derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1876178-A1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1876178-A1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292121-A1 | Cyanopyridine derivative and use thereof as medicine | DPYD, IDH1, TP53 | JAK2 1180/4885JAK3 3827/4885LIMK1 1660/4885 |
| US-20220233513-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | JAK2 87/4885JAK3 265/4885LIMK1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.